Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Feb. 28 '26)

Image
By G.M.

 


    Am J Respir Crit Care Med

  1. MENDEZ R, Gonzalez-Jimenez P, Latorre A, Piqueras M, et al
    The Long-term Pneumonia Mortality Index. An International Multicenter Derivation and Validation Study for Patients with Community-Acquired Pneumonia.
    Am J Respir Crit Care Med. 2026 Feb 21:aamag060. doi: 10.1093.
    PubMed         Abstract available

  2. GAERTNER VD, Ramin-Wright L, Waldmann AD, Belting C, et al
    The first breaths after birth-early lung function in healthy term infants.
    Am J Respir Crit Care Med. 2026 Jan 30:aamag008. doi: 10.1093.
    PubMed         Abstract available


    Ann Intern Med

  3. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
    COVID-19 Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
    Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
    PubMed         Abstract available


  4. Annals Video Summary - COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised.
    Ann Intern Med. 2026 Feb 24:e2600306VS. doi: 10.7326/ANNALS-26-00306.
    PubMed        


  5. Summary for Patients: COVID-19 Vaccines for 2025-2026.
    Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
    PubMed        

  6. DOBRESCU A, Pinte L, Sharifan A, Gadinger A, et al
    Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
    Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05044.
    PubMed         Abstract available


    Antiviral Res

  7. ZHANG T, Wang ZL, Li XY, Luo RH, et al
    Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity.
    Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376.
    PubMed         Abstract available


    Clin Infect Dis

  8. NELLORE A, Bajema K, Belden K, Blumberg D, et al
    IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19 infections in immunocompromised patients.
    Clin Infect Dis. 2026 Feb 25:ciag115. doi: 10.1093.
    PubMed         Abstract available


    Int J Infect Dis

  9. ALVES COSTA SILVA C, Pinheiro Bomfim A, Dutra Medeiros J, de Jesus Silva J, et al
    Corrigendum to "Nasal microbiota and clinical features in acute flu-like illness: COVID-19 status and long COVID follow-up" [International Journal of Infectious Diseases 162 (2026) 108196 https://doi.org/10.1016/j.ijid.2025.108196].
    Int J Infect Dis. 2026;165:108441.
    PubMed        


    J Infect

  10. ORDONEZ-MENA JM, Radin JM, Hoang U, Araujo AB, et al
    Epidemiology of virologically confirmed RSV, influenza and COVID-19 in adults in England, 2023-2024: Primary Care Observational Study of Acute Respiratory Infection (ObservatARI).
    J Infect. 2026 Feb 21:106714. doi: 10.1016/j.jinf.2026.106714.
    PubMed         Abstract available


    J Med Virol

  11. PHUONG LE UN, Chou RH, Lin CS, Lai HC, et al
    SARS-CoV-2 Main Protease Activates ERK1/2 Signaling to Facilitate MEG2-STAT3-Mediated Suppression of ACE2.
    J Med Virol. 2026;98:e70855.
    PubMed         Abstract available


  12. EXPRESSION OF CONCERN: The Emergence, Spread and Vanishing of a French SARS-CoV-2 Variant Exemplifies the Fate of RNA Virus Epidemics and Obeys the Mistigri Rule.
    J Med Virol. 2026;98:e70842.
    PubMed        


    J Virol

  13. NOORUZZAMAN M, Butt SL, Rani R, Ye C, et al
    The ORF6 accessory protein contributes to SARS-CoV-2 virulence and pathogenicity in the naturally susceptible feline model of infection.
    J Virol. 2026 Feb 27:e0064425. doi: 10.1128/jvi.00644.
    PubMed         Abstract available


    Nature

  14. VENTER M, Manuguerra JC, Watson JM, Fischer TK, et al
    COVID's origins: what we do and don't know.
    Nature. 2026;650:829-833.
    PubMed        
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »